Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 ...Middle East

- The updates of ASC22 Phase IIb study will be presented at the oral session during the International Liver Congress™ 2022 on Saturday, June 25, 2022 at 14:15, Beijing Time (Abstract Number: OS091) HANGZHOU, China and SHAOXING, China, June 15, 2022 /PRNewswire/ -- Ascletis Pharma Inc....

Hence then, the article about ascletis announces oral presentation on updates from phase iib clinical trial of asc22 a subcutaneous pd l1 antibody for functional cure of chronic hepatitis b at easl ilc 2022 was published today ( Thursday 16/06/2022 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 )

Also on site :

• ‘A little touch of luxury, it goes a long way’: Starbucks CEO sees the turn in the turnaround as human touch sings
• What channel is Atletico Madrid v Arsenal Champions League semi-final on? TV coverage, live stream and kick-off time
• Best-Selling Author’s Novel, Ranked ‘Readers’ Favorite Mystery and Thriller,’ Was Built on a Wild Premise